Author Correction: Influence of NOS3 rs2070744 genotypes on hepatocellular carcinoma patients treated with lenvatinib
An amendment to this paper has been published and can be accessed via a link at the top of the paper.
Guardado en:
Autores principales: | Shintaro Azuma, Haruki Uojima, Makoto Chuma, Xue Shao, Hisashi Hidaka, Takahide Nakazawa, Masaaki Kondo, Kazushi Numata, Shogo Iwabuchi, Makoto Kako, Shin Maeda, Wasaburo Koizumi, Koichiro Atsuda |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/0362b08815da47e4983a0d31f03ed2bd |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Therapeutic efficacy of lenvatinib in nonviral unresectable hepatocellular carcinoma
por: Tetsu Tomonari, et al.
Publicado: (2021) -
Multikinase inhibitors in the treatment of thyroid cancer: specific role of lenvatinib
por: Stjepanovic N, et al.
Publicado: (2014) -
Impact of modified albumin–bilirubin grade on survival in patients with HCC who received lenvatinib
por: Toshifumi Tada, et al.
Publicado: (2021) -
Treatment of metastatic hepatocellular carcinoma with lenvatinib. Case report and literature review
por: Konstantin V. Menshikov, et al.
Publicado: (2021) -
The immunomodulatory activity of lenvatinib prompts the survival of patients with advanced hepatocellular carcinoma
por: Jie Zhu, et al.
Publicado: (2021)